Gene delivery methods in cardiac gene therapy

Journal of Gene Medicine

Volumn 13, Issue 10, 2011, Pages 566-572

  Ishikawa, Kiyotake ^a   Tilemann, Lisa ^a   Fish, Kenneth ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac; Gene delivery; Gene therapy; Injection

Indexed keywords

AORTA CLAMPING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR GENE THERAPY; CATHETER; CORONARY ARTERY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART; HEART FAILURE; HUMANS; INJECTIONS;

RODENTIA;

EID: 80054955037     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1609     Document Type: Review

References (60)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: E46-E215.
2. Barker WH, Mullooly JP. Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006; 113: 799-805.
3. Goehringer C, Rutschow D, Bauer R, et al. Prevention of cardiomyopathy in δ-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res 2009; 82: 404-410.
4. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
5. Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006; 70: 70-78.
6. Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997; 36: 78-85.
7. Li W, Asokan A, Wu Z, et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008; 16: 1252-1260.
8. Beeri R. New Efficient Catheter-based system for myocardial gene delivery. Circulation 2002; 106: 1756-1759.
9. Fujii H, Li SH, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 2011; 32: 2075-2084.
10. Hernot S. Klibanov A. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-1166.
11. Raake PW, Hinkel R, Muller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008; 15: 12-17.
12. Logeart D, Hatem SN, Heimburger M, et al. How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther 2001; 12: 1601-1610.
13. Sasano T, Kikuchi K, McDonald AD, et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol 2007; 42: 954-961.
14. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
15. Parsa CJ, Reed RC, Walton GB, et al. Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. J Gene Med 2005; 7: 595-603.
16. Emani SM, Shah AS, Bowman MK, et al. Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 2003; 8: 306-313.
17. Byrne MJ, Power JM, Preovolos A, et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008; 15: 1550-1557.
18. Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007; 50: 253-260.
19. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000; 7: 232-240.
20. Raake P, von Degenfeld G, Hinkel R, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 2004; 44: 1124-1129.
21. Thompson CA, Nasseri BA, Makower J, et al. Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol 2003; 41: 1964-1971.
22. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-2683.
23. Luo Z, Palasis M, Yamakawa M, et al. Catheter-mediated delivery of adenoviral vectors expressing beta-adrenergic receptor kinase C-terminus inhibits intimal hyperplasia and luminal stenosis in rabbit iliac arteries. J Gene Med 2004; 6: 1061-1068.
24. Tahlil O, Brami M, Feldman LJ, et al. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33: 181-187.
25. Riessen R, Rahimizadeh H, Blessing E, et al. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 1993; 4: 749-758.
26. Barath P, Popov A, Dillehay GL, et al. Infiltrator Angioplasty Balloon Catheter: a device for combined angioplasty and intramural site-specific treatment. Cathet Cardiovasc Diagn 1997; 41: 333-341.
27. Morishige K, Shimokawa H, Yamawaki T, et al. Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol 2000; 35: 1040-1047.
28. Johnson TW, Wu YX, Herdeg C, et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol 2005; 25: 754-759.
29. Bridges CR, Burkman JM, Malekan R, et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann Thorac Surg 2002; 73: 1939-1946.
30. Bridges CR, Gopal K, Holt DE, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg 2005; 130: 1364.
31. Schneider C, Jaquet K, Malisius R, et al. Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J 2007; 28: 499-509.
32. Lau DH, Clausen C, Sosunov EA, et al. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation 2009; 119: 19-27.
33. Sanborn TA, Hackett NR, Lee LY, et al. Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv 2001; 52: 260-266.
34. Lederman RJ, Guttman MA, Peters DC, et al. Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation 2002; 105: 1282-1284.
35. Baklanov DV, de Muinck ED, Simons M, et al. Live 3D echo guidance of catheter-based endomyocardial injection. Catheter Cardiovasc Interv 2005; 65: 340-345.
36. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-2143.
37. Grossman PM, Han Z, Palasis M, et al. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv 2002; 55: 392-397.
38. Bish LT, Sleeper MM, Brainard B, et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008; 16: 1953-1959.
39. French BA, Mazur W, Geske RS, et al. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994; 90: 2414-2424.
40. Sosa E, Scanavacca M, d'Avila A, et al. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol 2000; 35: 1442-1449.
41. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2009; 120: 366-375.
42. Ayers GM, Rho TH, Ben-David J, et al. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 713-721.
43. Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 1999; 6: 683-688.
44. Ladage D, Turnbull IC, Ishikawa K, et al. Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 2011; Apr 21. [Epub ahead of print].
45. Uchida Y, Yanagisawa-Miwa A, Nakamura F, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J 1995; 130: 1182-1188.
46. Waxman S, Moreno R, Rowe KA, et al. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol 1999; 33: 2073-2077.
47. Han S, Hwang C. Pericardial approach for cardiac therapies: old practice with new ideas. Korean Circ J 2010; 40: 479-488.
48. March KL, Woody M, Mehdi K, et al. Efficient in vivo catheter-based pericardial gene transfer mediated by adenoviral vectors. Clin Cardiol 1999; 22: I23-I29.
49. Lamping KG, Rios CD, Chun JA, et al. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 1997; 272: H310-H317.
50. Ripa RS, Wang Y, Jorgensen E, et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006; 27: 1785-1792.
51. Fuchs S, Dib N, Cohen BM, et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 2006; 68: 372-378.
52. Yang ZJ, Zhang YR, Chen B, et al. Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol Biol Rep 2009; 36: 1323-1329.
53. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.
54. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42: 1339-1347.
55. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
56. Lathi KG, Vale PR, Losordo DW, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001; 92: 19-25.
57. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
58. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF (121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006; 13: 1503-1511.
59. Ishikawa K, Ladage D, Tilemann L, et al. Sterile abscess in the myocardium after direct intramyocardial injection related to gene therapy in a swine model. ISRN Cardiology 2011. doi:10.5402/2011/319453.
60. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008; 14: 355-367.